https://www.pharmaceutical-technology.com/data-insights/navtemadlin-kartos-therapeutics-chronic-idiopathic-myelofibrosis-primary-myelofibrosis-likelihood-of-approval/
Navtemadlin is under clinical development by Kartos Therapeutics and currently in Phase III for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis).
idiopathic myelofibrosiskartostherapeuticschronicprimary